Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of July 24, David Medical's stock closed at 13.3 yuan, with a PE ratio of 91.80, marking a new low in 88 days, and a total market capitalization of 3.83 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning David Medical at 104th place in the industry ranking [1][2] Group 2 - For Q1 2025, David Medical reported a revenue of 121 million yuan, reflecting a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year [2] - The company's gross profit margin stands at 57.13%, indicating its ability to maintain profitability despite declining revenues [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with a range of key products including incubators and neonatal monitoring devices [1]

Company Overview - David Medical's closing price on July 4 was 12.77 yuan, down 1.01%, with a rolling PE ratio of 88.15 times and a total market value of 3.678 billion yuan [1] - The company ranks 105th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1] Financial Performance - For Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year [2] - The sales gross margin was reported at 57.13% [2] Shareholding Structure - As of the Q1 2025 report, there are 2 institutional investors holding shares in David Medical, including 1 QFII and 1 insurance company, with a total holding of 1.2529 million shares valued at 1.5 million yuan [1] Product Portfolio - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, including incubators, radiant warmers, jaundice treatment devices, and various monitoring and therapeutic equipment [1] Industry Recognition - The company has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology and has received multiple honors, including "Famous Brand in Zhejiang Province" and "AAA Credit Rating Enterprise" [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the latest quarter [1][2] - As of June 30, David Medical's stock closed at 12.7 yuan, with a PE ratio of 87.66, which is significantly higher than the industry average of 50.61 [1][2] - The company has a total market capitalization of 36.58 billion yuan, ranking 105th in the medical device industry based on PE ratio [1][2] Group 2 - In the first quarter of 2025, David Medical reported an operating income of 1.21 billion yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% [2] - The company's sales gross margin stands at 57.13%, indicating a relatively high profitability despite the decline in revenue and profit [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators and neonatal monitoring devices [1]

6月3日，戴维医疗今日收盘12.77元，上涨2.49%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到88.15倍，创39天以来新低，总市值36.78亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)102戴维医疗88.1564.233.0936.78亿行业平均 50.8049.074.67108.36亿行业中值36.7136.842.4850.19亿1天益医疗-1758.71-3012.481.8822.41亿2澳华内 镜-655.90328.975.2569.12亿3诺唯赞-427.65-505.802.3591.52亿4爱朋医疗-397.87302.264.7932.65亿5博晖 创新-335.73532.763.5849.26亿6奥精医疗-136.87-200.611.8125.40亿7硕世生物-136.24-1990.831.2239.85亿 8睿昂基因-101.37-83.231.4413.12亿9康泰医学-88.33-74.633.1558.14亿10中红医疗-72.73-58.010.9250.55亿 11热景生物-55.61-64.074.10122.37亿 来源： ...

5月14日，戴维医疗今日收盘12.72元，上涨2.33%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到87.80倍，创26天以来新低，总市值36.63亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.21亿元，同比-22.00%；净利润2256.77万元， 同比-40.78%，销售毛利率57.13%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)102戴维医疗87.8063.973.0736.63亿行业平均 49.8447.964.65106.43亿行业中值36.6538.442.4547.58亿1天益医疗-1720.32-2946.711.8421.92亿2澳华内 镜-589.71295.774.7262.15亿3诺唯赞-415.01-490.852.2888.81亿4爱朋医疗-368.22279.744.4430.21亿5博晖 创新-326.27517.743.4847.87亿6硕世生物-135.93-1986.301.2239.76亿7奥精医疗-120.78-177.021.5922.41亿 8睿昂基因-97.79-80.291.3912.66亿9康泰医学-85. ...

4月1日，戴维医疗今日收盘12.77元，上涨3.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到41.73倍，总市值36.78亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入4.03亿元，同比-12.21%；净利润6330.79万元， 同比-48.44%，销售毛利率56.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)81戴维医疗41.7324.923.1336.78亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11 ...

Core Viewpoint - David Medical's stock closed at 12.39 yuan, down 2.21%, with a rolling PE ratio of 40.49 times and a total market value of 3.568 billion yuan, indicating a relatively high valuation compared to the industry average [1] Company Overview - Ningbo David Medical Equipment Co., Ltd. specializes in obstetric and pediatric care equipment and minimally invasive surgical instruments, with key products including infant incubators, radiant warmers, jaundice treatment devices, jaundice detection devices, and minimally invasive surgical instruments [1] - The company has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology and is one of the first in the industry to obtain CMDC and CE certifications [1] - David Medical has received multiple awards for its products at domestic and international exhibitions, with several technologies being industry-leading or first in the country [1] Financial Performance - For the third quarter of 2024, the company reported operating revenue of 403 million yuan, a year-on-year decrease of 12.21%, and a net profit of 63.31 million yuan, down 48.44% year-on-year, with a gross profit margin of 56.78% [1] Industry Comparison - The average PE ratio for the medical device industry is 45.22 times, with a median of 32.57 times, positioning David Medical at the 81st rank within the industry [2] - The company's static PE ratio is 24.17 times, and its price-to-book ratio is 3.04 [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a decline in stock price and profitability [1][2] - As of March 26, David Medical's stock closed at 12.68 yuan, down 1.25%, with a rolling price-to-earnings (PE) ratio of 41.44 times and a total market capitalization of 3.652 billion yuan [1] - The company ranks 82nd in the medical device industry, which has an average PE ratio of 45.14 times and a median of 31.99 times [1][2] Group 2 - For the third quarter of 2024, David Medical reported an operating income of 403 million yuan, a year-on-year decrease of 12.21%, and a net profit of 63.31 million yuan, down 48.44% year-on-year [2] - The company's sales gross margin stands at 56.78% [2] - David Medical specializes in obstetric and neonatal care equipment and minimally invasive surgical instruments, with key products including incubators and jaundice treatment devices [1]

戴维医疗收盘下跌2.41%，滚动市盈率41.02倍，总 市值36.14亿元 最新一期业绩显示，2024年三季报，公司实现营业收入4.03亿元，同比-12.21%；净利润6330.79万元， 同比-48.44%，销售毛利率56.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)83戴维医疗41.0224.493.0836.14亿行业平均 44.6149.194.84107.27亿行业中值31.8030.552.4747.66亿1硕世生物-1931.98-1931.981.2139.91亿2诺唯 赞-533.38-533.382.3090.68亿3利德曼-354.16169.901.5026.06亿4博晖创新-294.32-181.213.2445.17亿5康泰 医学-285.9333.552.9255.61亿6华大基因-223.96244.972.32227.58亿7奥精医疗-119.40-119.401.5221.63亿8 睿昂基因-82.41-82.411.2811.92亿9华大智造-54.96-54.964.12329.26亿10中红医疗-53.53-36.420.8547.66亿 11天智 ...